- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
2 promoters of Laurus Labs sell 70 lakh equity shares
Hyderabad: Laurus Labs Ltd. has recently announced that Dr.Satyanarayana Chava, Founder Promoter, CEO & ED, sold 52 lakh equity shares of the Company in the stock market at an average price of INR.368.59, per share, aggregating to INR 191.67 Crores and Mrs. Nagarani Chava, one of the promoters of the company sold 18 Lakh equity shares of the Company at an average price of 366.91 per...
Hyderabad: Laurus Labs Ltd. has recently announced that Dr.Satyanarayana Chava, Founder Promoter, CEO & ED, sold 52 lakh equity shares of the Company in the stock market at an average price of INR.368.59, per share, aggregating to INR 191.67 Crores and Mrs. Nagarani Chava, one of the promoters of the company sold 18 Lakh equity shares of the Company at an average price of 366.91 per share at an aggregate value of INR 66.04 Crores, together 1.3% of the paid up capital of the Company.
Significant part of the above amount shall be utilized to release the pledge on their equity shares of the Company.
It may be recalled that the above promoters have purchased around 3% of the then paid up capital of the Company in the year 2018.
Read also: Laurus Labs bags Golden Peacock Award for Excellence in Corporate Governance 2020
Laurus Labs is an Indian pharmaceutical company headquartered in Hyderabad.
The Company's major focus areas include anti-retroviral, Hepatitis C and Oncology drugs.
Most of the Laurus Labs manufacturing facilities are approved by major regulatory authorities USFDA, WHO-Geneva, UK-MHRA, etc.
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751